UK-based cancer therapy developer Celleron Therapeutics is lining up $16m in funding from a consortium including NHN Investment, the corporate venture capital arm of internet company Naver, the Korea Herald has reported.
Korea Investment Partners is investing $6m while NHN and two unnamed venture capital firms based in Korea are providing the other $10m.
Founded in 2005, Celleron is working on personalised cancer treatments, including a platform known as CXD101. The company will use the cash to enter the therapy…
